[
    {
        "題別": "單",
        "題號": "1",
        "題目": "兒童（<18歲）的末期腎病成因，以下列何者最多？",
        "選項": [
            "A. 糖尿病（Diabetes Mellitus）",
            "B. 慢性腎絲球腎炎（Chronic Glomerulonephritis）",
            "C. 高血壓性腎硬化（Hypertension Nephrosclerosis）",
            "D. 先天性異常（Congenital Anomaly）",
            "E. lgA腎病變（lgA Nephropathy）"
        ],
        "答案": "D",
        "出處": "Smith's General Urology 19th ed,\n2020, Chap 32"
    },
    {
        "題別": "單",
        "題號": "2",
        "題目": "腎移植手術有關者何者為非？",
        "選項": [
            "A. 一般而言移植腎置於腸骨窩（iliac fossa）",
            "B. 基於血管走向考量，左側腸骨窩為優先選擇",
            "C. 步驟順序上以先接靜脈再接動脈較常使用",
            "D. 一般不必使用肝素（Heparin）",
            "E. 除特殊狀況外不常使用受腎者的輸尿管引留尿液"
        ],
        "答案": "B",
        "出處": "Smith's General Urology 19th ed\n2020., Chap 36"
    },
    {
        "題別": "單",
        "題號": "3",
        "題目": "腦死判定，不包括那一項？",
        "選項": [
            "A. 頭一眼反射消失",
            "B. 瞳孔對光反射消失",
            "C. 眼角膜反射消失",
            "D. 前庭動眼反射消失",
            "E. 對身體任何部位之疼痛刺激，不能引起運動反應"
        ],
        "答案": "E",
        "出處": "腦死判定準則。衛福部\n2012/12/17。衛署醫字第\n101026779號"
    },
    {
        "題別": "單",
        "題號": "4",
        "題目": "腦死病人，仍有可能以下何種反應？",
        "選項": [
            "A. 自行呼吸",
            "B. 氣管抽痰時，有咳嗽反射",
            "C. 脊椎反射存在",
            "D. 瞳孔放大，但對光有反應",
            "E. 眼球會自行轉動"
        ],
        "答案": "C",
        "出處": "腦死判定準則。衛福部\n2012/12/17。衛署醫字第\n101026780號"
    },
    {
        "題別": "單",
        "題號": "5",
        "題目": "以下何者是判定腦死必須的？",
        "選項": [
            "A. 腦電圖（EEG）",
            "B. 腦血管攝影",
            "C. 頭部電腦斷層",
            "D. 能否自行呼吸測試",
            "E. 心電圖（EKG）"
        ],
        "答案": "D",
        "出處": "腦死判定準則。衛福部\n2012/12/17。衛署醫字第\n101026781號"
    },
    {
        "題別": "單",
        "題號": "6",
        "題目": "下列何種藥物會增加環孢靈（Cyclosporine）濃度？",
        "選項": [
            "A. Phenytoin",
            "B. Erythromycin",
            "C. Rifampicin",
            "D. Phenobarbital",
            "E. Carbamazepine"
        ],
        "答案": "B",
        "出處": "Maddrey. Transplantation of the\nLiver. 3rd ed. 2001. p204-205"
    },
    {
        "題別": "單",
        "題號": "7",
        "題目": "何種病患不適合作腎臟移植之捐贈者？",
        "選項": [
            "A. 惡性腦瘤致腦死亡，無其他器官轉移者",
            "B. 一等血親，組織配對半數相合者",
            "C. 蜘蛛網膜下出血致腦死亡者",
            "D. 體溫低於35度之病人",
            "E. 出血性腦中風致腦死亡者"
        ],
        "答案": "D",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 6"
    },
    {
        "題別": "單",
        "題號": "8",
        "題目": "三十歲女性慢性腎衰竭病人接受腎臟移植，移植後接受 Methylprednisolone, Antilymphocyte globulin及Imuran作 Induction Therapy，一週後腎功能穩定（Cr:1.4 mg/dl, Hb:11.4 mg/dl, Platelet:143x10³ /mm³），改使用 cyclosporine, prednisolone, Imuran治療，兩日後尿量減少 ，下肢出現紫斑，抽血檢查發現，Cr:5.3 mg/dl, Hb:4.5 mg/dl, Platelet:6x10³ /mm³, LDH:1460 IU/dl，血液抹片發 現許多破裂紅血球（fragmented RBC），下列何者為其診 斷？",
        "選項": [
            "A. Acute rejection",
            "B. Upper gastroenteric bleeding",
            "C. Cyclosporine induced thrombotic microangiopathy",
            "D. De novo glomerulonephropathy",
            "E. Imuran induced bone marrow suppression"
        ],
        "答案": "C",
        "出處": "Oxford Textbook of Clinical\nNephrology. 4rd ed., 2016, chap 13"
    },
    {
        "題別": "單",
        "題號": "9",
        "題目": "在腎臟移植後一個月內，何種感染較少發生？",
        "選項": [
            "A. 細菌性肺炎",
            "B. 傷口感染",
            "C. 泌尿道感染",
            "D. 隱球菌感染（cryptococcal infection）",
            "E. B型肝炎活化"
        ],
        "答案": "D",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 27"
    },
    {
        "題別": "單",
        "題號": "10",
        "題目": "腎臟移植後三天拔除導尿管，病人小便量減少，移植位置 腫脹，腎功能變差，經超音波檢查發現移植腎臟下方有低 回音區，腎盞擴張，請問下一步應該作何檢查？",
        "選項": [
            "A. 經引流管作引流液檢查並與血液及尿液比較, creatinine, Na的濃度",
            "B. 作Cystography",
            "C. 作移植腎臟之Percutaneous nephrostomy",
            "D. 馬上開刀找原因",
            "E. 使用methylprednisolone"
        ],
        "答案": "A",
        "出處": "Barry K, Principles and Practice of\nRenal Transplantation., 2000, p231-\n247"
    },
    {
        "題別": "單",
        "題號": "11",
        "題目": "下列抗排斥藥物作用機轉何者為非？",
        "選項": [
            "A. Cyclosporine blocks Ca²+-dependent T cell activation pathway via binding to calcineurin",
            "B. Rapamycin inhibits pyrimidine synthesis",
            "C. Azathioprine inhibits purine synthesis",
            "D. Corticosteroid blocks cytokine gene expression",
            "E. mycophenolate mofetil (MMF) inhibits a lymphocyte specific guanosine synthesis pathway"
        ],
        "答案": "B",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "12",
        "題目": "腎移植前，下列何種情況，受腎者不需要切除原有的腎 臟？",
        "選項": [
            "A. 腎性高血壓",
            "B. 腎結石",
            "C. 嚴重蛋白尿",
            "D. 巨大多囊性腎",
            "E. 腎絲球性腎萎縮"
        ],
        "答案": "E",
        "出處": "Campbell’s Urology, 12th ed.,2020,\np????"
    },
    {
        "題別": "單",
        "題號": "13",
        "題目": "由捐獻者摘取腎臟時，其注意事項中，最少有關係者為？",
        "選項": [
            "A. 維持正常血壓",
            "B. 減少溫缺氧時間（minimize warm ischemia time）",
            "C. 保存腎血管",
            "D. 保存輸尿管血管",
            "E. 保存全部腎周圍脂肪組織"
        ],
        "答案": "E",
        "出處": "Campbell’s Urology, 12th ed.,2020,\np????"
    },
    {
        "題別": "單",
        "題號": "14",
        "題目": "cyclosporine抗排斥葯，其主要作用機轉是：",
        "選項": [
            "A. 抑制macrophage產生IL-1",
            "B. 抑制DNA&RNA生產",
            "C. 抑制helper T-cell產生IL-2",
            "D. 分辨lymphocyte",
            "E. 抑制IL-2和T-cells的結合"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "15",
        "題目": "移植腎喪失功能最常見的原因是：",
        "選項": [
            "A. 排斥",
            "B. 抗排斥葯過量中毒",
            "C. 腎動脈狹窄",
            "D. 腎靜脈栓塞",
            "E. 膀胱輸尿管逆流"
        ],
        "答案": "A",
        "出處": "Campbell's Urology, 12th ed.,2020,\np????"
    },
    {
        "題別": "單",
        "題號": "16",
        "題目": "接受屍腎移植患者的條件，下列何者是最少考慮的因素？",
        "選項": [
            "A. 血型",
            "B. 淋巴球毒殺試驗（Lymphocytotoxic test）",
            "C. 體重",
            "D. HLA-match",
            "E. 性別"
        ],
        "答案": "E",
        "出處": "Campbell's Urology, 12th ed.,2020,\np????"
    },
    {
        "題別": "單",
        "題號": "17",
        "題目": "下列有關腎臟移植長期存活率，何者為誤？",
        "選項": [
            "A. 移植次數越多結果越好",
            "B. 活體移植比屍體移植結果好",
            "C. 六個HLA組織抗原完全相同的腎臟移植結果最好",
            "D. 血型配合的移植較不配合的結果好",
            "E. 近十年的移植結果比前二十年好"
        ],
        "答案": "A",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 39"
    },
    {
        "題別": "單",
        "題號": "18",
        "題目": "器官捐贈者（donor）與接受者（recipient）間主要組織配 對抗原（HLA）配對以下列何者最重要？",
        "選項": [
            "A. HLA-A",
            "B. HLA-B",
            "C. HLA-C",
            "D. HLA-DR",
            "E. HLA-DQ"
        ],
        "答案": "D",
        "出處": "Transplantation Surgery. 1st ed. By\nJ.L.R. Forsythe, 2014, , chap 2"
    },
    {
        "題別": "單",
        "題號": "19",
        "題目": "下列何者非環孢靈（Cyclosporine）之常見副作用？",
        "選項": [
            "A. 腎毒性",
            "B. 肝毒性",
            "C. 白血球減少",
            "D. 多毛症",
            "E. 牙齦增生"
        ],
        "答案": "C",
        "出處": "Transplantation Surgery. 1st ed. By\nJ.L.R. Forsythe, 2014, , chap 3"
    },
    {
        "題別": "單",
        "題號": "20",
        "題目": "捐贈器官可保存的時間以下列何者最短：",
        "選項": [
            "A. 腎臟",
            "B. 肝臟",
            "C. 胰臟",
            "D. 心臟",
            "E. 角膜"
        ],
        "答案": "D",
        "出處": "Transplantation Surgery. 1st ed. By\nJ.L.R. Forsythe, 2014, , chap 4"
    },
    {
        "題別": "單",
        "題號": "21",
        "題目": "移植後發生的白血球惡性腫瘤以下列何者最常見？",
        "選項": [
            "A. 何杰金氏淋巴瘤",
            "B. 小細胞淋巴瘤",
            "C. 非何杰金氏淋巴瘤",
            "D. 骨髓瘤",
            "E. 白血病（血癌）"
        ],
        "答案": "C",
        "出處": "Transplantation Surgery. 1st ed. By\nJ.L.R. Forsythe, 2014, chap 25"
    },
    {
        "題別": "單",
        "題號": "22",
        "題目": "下列何者對屍體器官捐贈者術前的處理是不妥的？",
        "選項": [
            "A. 保持體溫在32-33℃，減少代謝",
            "B. 保持收縮壓至少100 mmHg",
            "C. 多巴胺（dopamine）的最佳使用劑量在10μg/kg/min以 下",
            "D. 維持尿量在100cc/小時左右",
            "E. 適度治療尿崩症"
        ],
        "答案": "A",
        "出處": "Transplantation Surgery. 1st ed. By\nJ.L.R. Forsythe, 2014, chap 4"
    },
    {
        "題別": "單",
        "題號": "23",
        "題目": "安全及有效評估急性期肺移植後排斥方法為下列何者？",
        "選項": [
            "A. Bronchoalveolar lavage",
            "B. 臨床症狀",
            "C. Transbronchial lung biopsy",
            "D. 檢測blood gas氧氣值",
            "E. Open lung biopsy"
        ],
        "答案": "C",
        "出處": "Hakim. Transplantation Surgery,\n2021, 2nd ed, 127-147"
    },
    {
        "題別": "單",
        "題號": "24",
        "題目": "關於免疫抑制劑以下何者為非？",
        "選項": [
            "A. Azathioprine會增加皮膚癌的機會",
            "B. Cyclosporine可直接抑制macrophage產生IL-1",
            "C. OKT3會使T cell釋出tumor necrosis factor（TNF）而引 起發燒、畏寒、低血壓等症狀",
            "D. FK506是黴菌衍生物",
            "E. Pulse steroid therapy可能出現高血糖、高血壓、睡眠因 擾等症狀"
        ],
        "答案": "B",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "25",
        "題目": "關於器官移植後之巨大細胞病毒感染（cytomegalovirus infection），以下何者為非？",
        "選項": [
            "A. 可用ganciclovir (DHPG) 20 mg/kg/day靜脈注射10~14天",
            "B. 初次感染較再發作症狀輕",
            "C. 可用Acyclovir 800~3200 mg口服預防",
            "D. 避免使用血液抗體陽性（seropositive）的器官於陰性的 受贈者",
            "E. 可能出現的症狀為全身性或是局限於肺、視網膜、腸胃 道或肝臟"
        ],
        "答案": "B",
        "出處": "Transplantation Surgery : Current\nDilemmaas, 2ed, 2001, p 219-231;\nThomas E. Starzl Transplantation\nTextbook, 2nd ed., 2018. Ch. 28, p.\n560"
    },
    {
        "題別": "單",
        "題號": "26",
        "題目": "因為各種醫療科技之進步，腎臟移植的受贈者條件已經越 來越寬鬆了，但一般而言，以下何者仍然不建議接受腎移 植手術？",
        "選項": [
            "A. 預期存活（Life expectancy）在五年之內",
            "B. 年紀在65歲以上",
            "C. 冠狀動脈血管疾病並接受過繞道（Bypass）手術者",
            "D. 膀胱癌患者接受手術治療後觀察五年無復發跡象者",
            "E. B型或C型肝炎帶原者或紅斑性狼瘡（SLE）的患者"
        ],
        "答案": "A",
        "出處": "Clinical Management of the\nTransplantation Patient, 2001, p75-\n83; Abdominal Organ\nTransplantation, 1st ed., 2016, p74"
    },
    {
        "題別": "單",
        "題號": "27",
        "題目": "以下有關移植免疫學的敘述何者有誤？",
        "選項": [
            "A. 移植抗原（Transplantation Antigen）是表達在細胞表面 的一些醣蛋白（Glycoprotein）稱作Human Leukocyte Antigen (HLA)",
            "B. HLA 的遺傳密碼是由Chromosome 18來管轄",
            "C. 人類對於移植器官之排斥即起因於不同的HLA所致，而 其實這種排斥機轉和人體對於細菌的抵抗原理是類似的",
            "D. Hyperacute rejection和輸血反應類似，都屬於一種體液 反應（humoral response）",
            "E. 因為交叉比對（cross match）技術之成熟，已經使 hypercute rejection的可能性大幅下降到1/1000"
        ],
        "答案": "B",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "28",
        "題目": "有關Acute rejection的敘述，何者有誤？",
        "選項": [
            "A. 在術後第一周到數個月內均可能發生，最常列入的鑑別 診斷包括Acute tubular Necrosis (ATN) 和輸尿管阻塞",
            "B. 大多數的Acute rejection可以用藥成功控制，目前只有少 於10﹪的病人移植腎會因Acute rejection而喪失",
            "C. T-Lymphocyte是與Acute rejection最有關的細胞",
            "D. 受腎者的CD8+細胞在Interleukin-1的幫助下破壞移植腎",
            "E. Acute rejection發生時，除了必須有Interleukin-1的幫助 之外，受腎者的CD4+細胞還必須有捐贈者的Class II Antigen刺激，才會發生排斥反應"
        ],
        "答案": "D",
        "出處": "Campbell’s Urology, 12th ed.,2020,\np????"
    },
    {
        "題別": "單",
        "題號": "29",
        "題目": "雖然正確機轉尚未完全瞭解，但目前對於Chronic rejection 仍有以下諸發現，請指出錯誤者：",
        "選項": [
            "A. chronic rejction仍為長期移植腎功能喪失的主因之一",
            "B. 病理變化包括Arteriosclerosis of vessel, tubular fibrosis 等等",
            "C. 移植手術時發生的ischemic-reperfusion injury目前認為 和移植腎的Acute Tubular Necrosis有關，而與chronic rejection無關",
            "D. Macrophage的浸潤是late graft rejection的組織學特徵",
            "E. 一些體內的介質（mediator）例如Interleukin-1, TNF , chemokine MCP共同引發chronic inflammation的過程，其 後發生Scarring於是不可逆的移植腎功能喪失（graft failure）發生"
        ],
        "答案": "C",
        "出處": "Janeway's Immunobiology -9th\nedition, 2017, chap 10"
    },
    {
        "題別": "單",
        "題號": "30",
        "題目": "何者為最常發生在肝臟移植一個月內的感染？",
        "選項": [
            "A. Tuberculosis",
            "B. Bacterial infection",
            "C. Fungal infection",
            "D. Viral infection",
            "E. Peumocystis"
        ],
        "答案": "B",
        "出處": "Medical Care of the Liver Transplant\nPatient. By Killenberg, 3rd edition,\n2006. p???"
    },
    {
        "題別": "組合題",
        "題號": "31",
        "題目": "【組合題31-32】一位40歲女性因尿毒症接受腎臟移植，使 用tacrolimus, mycophenolate mofetil及Prednisolone作免 疫抑制劑，參個月以後感覺倦怠、關節酸痛、微發燒，住 院生化檢查血清肌酸酐升高為3.5 mg/dl，膽紅素為1.0 mg/dl，白血球10800，分類顯示多核白血球60﹪，淋巴球 26﹪，嗜伊紅球8﹪，單核球5﹪，嗜鹼性白血球1﹪，血清 環孢靈濃度為87 ng/ml，排尿減少。此病人之症狀顯示較可 能有：",
        "選項": [
            "A. 病毒感染",
            "B. 急性排斥",
            "C. 環孢靈中毒",
            "D. 寄生蟲感染",
            "E. 淋巴囊腫"
        ],
        "答案": "B",
        "出處": "臨床題"
    },
    {
        "題別": "組合題",
        "題號": "32",
        "題目": "【組合題31-32】上述病人下一步驟較佳之處理方式為：",
        "選項": [
            "A. 立刻給予大量類固醇注射治療",
            "B. 作病毒血清試驗檢查",
            "C. 立刻給予驅蟲藥",
            "D. 安排作腎臟穿刺切片檢查",
            "E. 安排作移植腎電腦斷層檢查"
        ],
        "答案": "D",
        "出處": "臨床題"
    },
    {
        "題別": "組合題",
        "題號": "33",
        "題目": "【組合題33-34】52歲男性因B型肝炎病毒感染導致肝硬化 ，接受全肝臟移植，術後第二天拔除氣管內管，肝功能明 顯改善，術後第四天自腹部引流管每天有2000毫升以上淡 黃色之引流液，其磁振影像檢查如圖所示，此一病人之診 斷為：",
        "選項": [
            "A. 急性排斥",
            "B. 門靜脈血管狹窄",
            "C. 肝靜脈血管狹窄",
            "D. 腹部感染",
            "E. 下腔靜脈狹窄"
        ],
        "答案": "C",
        "出處": "臨床題"
    },
    {
        "題別": "組合題",
        "題號": "34",
        "題目": "【組合題33-34】上題陳述之病人的處理方式：",
        "選項": [
            "A. 給予大劑量抗排斥藥",
            "B. 肝臟切片檢查",
            "C. 施以血管支架治療",
            "D. 重新開腹作血管分流手術",
            "E. 腹部抗生素灌流"
        ],
        "答案": "C",
        "出處": "臨床題"
    },
    {
        "題別": "單",
        "題號": "35",
        "題目": "捐肝媽媽的肝炎指標為HBsAg(-), anti-HBc(+), anti-HBs(-) ，病童為HBsAg(-), anti-HBc(-), anti-HBS (-)， 移植中及移 植後處理方式為：",
        "選項": [
            "A. 不必給予特別預防",
            "B. 可給予肝炎疫苗注射即可",
            "C. 病童給予HBIG 及 lamivudin",
            "D. 單次給與抗B型肝炎血清球蛋白（HBIG）",
            "E. 必須長期給予HBIG"
        ],
        "答案": "C",
        "出處": "臨床題"
    },
    {
        "題別": "單",
        "題號": "36",
        "題目": "男子車禍腦部重創送醫，家屬有意願捐贈器官，其所做的 檢查如下：體重60kg，血型B型，anti-HCV(-), anti- HBC(+), anti-HBs(-), anti HIV(-), anti-CMV IgG(-), Apnea test 沒有呼吸反射，brain stem 反射(-)，經腦死判定後，下 列答案何者正確？",
        "選項": [
            "A. 他的器官可以捐給A, B, AB, O 型之受贈者",
            "B. 他的肝臟不可以移植給一位10kg之受贈者",
            "C. 他的肝臟仍有可能帶有HBsAg，而有傳染性",
            "D. 捐贈器官不須檢查官相驗開具證明",
            "E. 摘取器官時，時間優先順序為 肝＞肺＞心＞腎"
        ],
        "答案": "C",
        "出處": "臨床題"
    },
    {
        "題別": "單",
        "題號": "37",
        "題目": "關於心臟移植抗排斥藥物，下列何者為抑制 IL-2 作用？ (1) Cyclosporin A (2) Azathioprine (3) Tacrolimus (4) Rapamycin",
        "選項": [
            "A. (1)(2)(3)皆正確",
            "B. (1)(3)(4)皆正確",
            "C. 僅(1)正確",
            "D. (2)(3)(4)皆正確",
            "E. (1)(2)(3)(4)皆正確"
        ],
        "答案": "B",
        "出處": "Reference: Kirklin, Cardiac\nSurgery, 4th ed, 2013, chap 21"
    },
    {
        "題別": "單",
        "題號": "38",
        "題目": "有關單獨心臟移植之適應症，下列何者為非？",
        "選項": [
            "A. 末期心臟衰竭，無法脫離強心劑支持",
            "B. 複雜性先天性心臟病,無法矯正，併進行性心臟衰竭",
            "C. 心因性休克，需機械性循環輔助，無合併其他器官之衰 竭",
            "D. 嚴重肺高壓，肺血管阻力 ＞ 6 Wood units",
            "E. 無法切除的心臟腫瘤，並具低遠端轉移之機率"
        ],
        "答案": "D",
        "出處": "Reference: Kirklin, Cardiac\nSurgery, 4th ed, 2013, chap 21"
    },
    {
        "題別": "單",
        "題號": "39",
        "題目": "有關心臟移植下列敘述可者錯誤？",
        "選項": [
            "A. 心臟衰竭需 on ECMO 及mechanical ventilation support 之病人屬於UNOS recipient status criteria 的status IA",
            "B. Donor- recipient matching 最重要條件為ABO 血型及 patient size",
            "C. Irreversible pulmolnary hypertension 為 heterotopic heart transplantation主要適應症",
            "D. Endocardial biopsy 為診斷 rejection 最重要的檢查",
            "E. 移植後心臟因為 autonervic system denervation 所以心 跳最好維持於60-70跳左右"
        ],
        "答案": "E",
        "出處": "Reference: Kirklin, Cardiac\nSurgery, 4th ed, 2013, chap 21"
    },
    {
        "題別": "單",
        "題號": "40",
        "題目": "爲避免超急性排斥（Hyperacute rejection）而進行淋巴球 毒性試驗（Lymphocytotoxic test）乃是將下列何者交叉配 對？",
        "選項": [
            "A. 捐贈者的淋巴球和接受者的血清",
            "B. 捐贈者的血清和接受者的血清",
            "C. 捐贈者的血清和接受者的淋巴球",
            "D. 捐贈者的淋巴球和接受者的淋巴球",
            "E. 以上皆是"
        ],
        "答案": "A",
        "出處": "Reference: Kirklin, Cardiac\nSurgery, 4th ed, 2013, chap 21"
    },
    {
        "題別": "單",
        "題號": "41",
        "題目": "下列何種排斥最難從心肌內膜切片檢查（Endomyocardial biopsy）獲得診斷？",
        "選項": [
            "A. 慢性排斥（Chronic rejection）",
            "B. 急性細胞排斥（Acute cellular rejection）",
            "C. 急性體液排斥（Acute humoral rejection）",
            "D. 超急性排斥（Hyoperacute rejection）",
            "E. 急性血管排斥（Acute vascular rejection）"
        ],
        "答案": "A",
        "出處": "Reference: Kirklin, Cardiac\nSurgery, 4th ed, 2013, chap 21"
    },
    {
        "題別": "單",
        "題號": "42",
        "題目": "有關常見的抗排斥藥物機轉，何者為非？",
        "選項": [
            "A. OKT3是一種monoclonal antibody，會與T-cell receptor 結合，快速清除血中的T-cell",
            "B. Cyclosporine及Tarcolimus皆為Calcineurin inhibitor， 作用在T-helper cell內",
            "C. Sirolimus亦作用在T-helper cell，抑制IL-II的分泌",
            "D. MMF及AZT作用在cytotoxic-T-cell內，減少DNA 的合成 及T-cell的proliferation",
            "E. steroid 亦作用在 antigen present cell 上"
        ],
        "答案": "C",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019 , chap 11"
    },
    {
        "題別": "單",
        "題號": "43",
        "題目": "有關器官移植之免疫及用藥，下列何者為誤？",
        "選項": [
            "A. 最早有效之免疫抑制劑組合為1962年之 cyclosporine 及 類固醇",
            "B. Ｔ淋巴球啟動排斥反應乃由dendritic cells及吞噬細胞作 為抗原前處理誘發而開始",
            "C. 淋巴球活化抑制劑包含了cyclosporine及 tacrolimus (FK-506)",
            "D. 淋巴球代謝抑制劑包含了azathioprine 及 mycophenolate mofetil （MMF）",
            "E. cyclosporine 為非骨髓抑制性免疫抑制劑"
        ],
        "答案": "A",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "44",
        "題目": "下列何者為監測胰臟排斥的理想標記 (ideal marker for pancreas rejection)?",
        "選項": [
            "A. 血糖 (Blood sugar)",
            "B. 血中C-peptide (Blood C-peptide)",
            "C. 血中澱粉酶(Blood amylase)",
            "D. 血中胰島素(Blood insulin)",
            "E. 目前並沒有胰臟排斥的理想標記"
        ],
        "答案": "E",
        "出處": "Hakim, Transplantation Surgery.\n2nd ed, Springer.2021, p205-217"
    },
    {
        "題別": "單",
        "題號": "45",
        "題目": "器官移植後使用抗排斥藥，最易產生巨細胞病毒(CMV: cytomegalovirus)感染的為下列何種捐贈者及受捐者之CMV 血清狀態？",
        "選項": [
            "(A). 捐贈者陰性及受贈者陰性（Donor (-) and Recipeint (- )）",
            "(B). 捐贈者陰性及受贈者陽性 （Donor (-) and Recipeint (+)）",
            "(C). 捐贈者陽性及受贈者陽性（Donor (+) and Recipeint (+)）",
            "(D). 捐贈者陽性及受贈者陰性（Donor (+) and Recipeint (- )）",
            "(E). 捐贈者及受贈者曾否有CMV感染並無關"
        ],
        "答案": "D",
        "出處": "Transplant Infections 3rd ed. 2010,\npp: 328-363"
    },
    {
        "題別": "單",
        "題號": "46",
        "題目": "下列何種胰臟移植成功率較高？",
        "選項": [
            "A. 胰島細胞移植 (Islet cell transplant)",
            "B. 胰臟單獨移植 (Pancreas transplant alone)",
            "C. 腎移植後的胰臟移植(Pancreas after kidney transplant)",
            "D. 胰腎同時移植 (Simultaneous pancreas kidney transplant)",
            "E. 胰臟再移植 (Pancreas re-transplant)"
        ],
        "答案": "D",
        "出處": "Hakim, Transplantation Surgery.\n2nd ed, Springer.2021 p205-217"
    },
    {
        "題別": "單",
        "題號": "47",
        "題目": "有關肝臟移植後一週內之患者，其血行動力學數據穩定， 且臨床上無明顯出血症狀時，則其照顧，下列何者正確？",
        "選項": [
            "A. 大部分之患者，術後早期之CVP值保持在4到8 cmH2O 即可，若CVP值超過14 cmH2O，則應考慮使用血液透析或 CVVH。",
            "B. 在小兒患者，為保持足夠的血液攜氧能力，因此若 Hematocrit只有28%，則要儘量輸血讓血液之Hematocrit 保持在40%以上。",
            "C. 雖然臨床上無明顯出血症狀，但由於植入之肝臟在術後 早期很難製造充足的凝血因子，因此要儘量輸以新鮮冷凍 血漿，讓Prothrombin time 保持在18秒之內及INR保持在 1.8之內 。",
            "D. 由於肝臟有兩套血管供應，因此只要portal vein 確定通 暢即可，hepatic artery即使thrombosis，亦可保持觀察即 可。",
            "E. 代謝性鹼中毒，很少造成腎血管收縮，因此不需要處 理。"
        ],
        "答案": "A",
        "出處": "Busuttil RW, Transplantation of the\nLiver, 3nd ed.Elsevier Saunders,\n2014, chap 71"
    },
    {
        "題別": "單",
        "題號": "48",
        "題目": "下列何種病人目前是臺灣胰臟移植適應症？ 1. 第一型糖尿病，合併腎衰竭者，或產生其他糖尿病合併 症 2. 第一型糖尿病，常合併低血糖症 3. 第二型糖尿病，已使用胰島素，且合併腎衰竭者 4. 第一型糖尿病，尚未產生糖尿病合併症 5. 第一型糖尿病，產生其他糖尿病合併症 6. 第二型糖尿病，服用口服降血糖藥控制",
        "選項": [
            "A. 1,2,3",
            "B. 1,3,5,6",
            "C. 1,2,3,4",
            "D. 1,2,3,5",
            "E. 1,2,3,4,5,6"
        ],
        "答案": "D",
        "出處": "臨床題"
    },
    {
        "題別": "單",
        "題號": "49",
        "題目": "器官移植後病人發燒，肺部x光 (CXR)顯示兩側對稱性間質 性浸潤（bilateral symmetric interstitial infiltration），其較 可能診斷為何？ 1. Cytomegalovirus pneumonia 2. Cryptococcal pneumonia 3. Klebsiella pneumonia 4. Pneumocystis jiroveci pneumonia 5. Candida pneumonia",
        "選項": [
            "A. 1,2",
            "B. 1,3",
            "C. 1,4",
            "D. 1,5",
            "E. 4,5"
        ],
        "答案": "C",
        "出處": "臨床題"
    },
    {
        "題別": "單",
        "題號": "50",
        "題目": "胰臟移植後，導致病人死亡最常見的原因為？",
        "選項": [
            "A. 惡性腫瘤",
            "B. 感染",
            "C. 心血管疾病",
            "D. 藥物中毒",
            "E. 器官排斥"
        ],
        "答案": "C",
        "出處": "Hakim, Transplantation Surgery.\n2nd ed, Springer.2021 p205-217"
    },
    {
        "題別": "單",
        "題號": "51",
        "題目": "有關器官移植後使用抗排斥藥之副作用，下列何者不正 確？",
        "選項": [
            "A. 增加病毒感染的機會",
            "B. 增加伺機性感染的機會",
            "C. 增加惡性腫瘤發生的機會",
            "D. 環孢靈及tacrolimus長期使用會有腎毒性",
            "E. 肝癌病人肝臟移植後肝癌復發率較肝癌切除病人為高"
        ],
        "答案": "E",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "單",
        "題號": "52",
        "題目": "下列那項不是肝臟移植之適應症？",
        "選項": [
            "A. primary biliary cirrhosis",
            "B. hepatitis C related liver cirrhosis",
            "C. biliary atresia",
            "D. liver cirrhosis due to heart failure",
            "E. hepatocellular carcinoma"
        ],
        "答案": "D",
        "出處": "Sabiston: Textbook of Surgery,\n20ed, 2017, Chapter 25, page 638-\n639"
    },
    {
        "題別": "單",
        "題號": "53",
        "題目": "下列那一種免疫抑制藥物可能有致畸胎性，準備要懷孕的 移植病友不宜使用？",
        "選項": [
            "A. Tacrolimus",
            "B. Mycophenolate mofetil",
            "C. Prednisolone",
            "D. Cyclosporine",
            "E. Intravenous immunoglobulin"
        ],
        "答案": "B",
        "出處": "J Clin Pharm Ther. 2021\nJun;46(3):744-753."
    },
    {
        "題別": "單",
        "題號": "54",
        "題目": "免疫抑制藥物anti-lymphocyte antibody不宜和下列那一種 藥物合併使用？",
        "選項": [
            "A. Tacrolimus",
            "B. Intravenous immunoglobulin (IVIG)",
            "C. Basiliximab (Simulect, anti-CD25 antibody)",
            "D. Rituximab (Mabthera, anti-CD20 antobody)",
            "E. Cyclosporine"
        ],
        "答案": "D",
        "出處": "J Clin Pharm Ther. 2021\nJun;46(3):744-753"
    },
    {
        "題別": "單",
        "題號": "55",
        "題目": "移植前評估，那一項檢查是為了避免hyperacute rejection(超急性排斥)？",
        "選項": [
            "A. Cross matching",
            "B. HLA tissue typing",
            "C. VDRL screening",
            "D. CMV screening",
            "E. Cardiac perfusion scan"
        ],
        "答案": "A",
        "出處": "Peter J. Morris Kidney\nTransplantation-Principles and\nPractice. 2020, 8th ed, Chapter 10."
    },
    {
        "題別": "單",
        "題號": "56",
        "題目": "從捐贈者取下的腎臟，最好使用那一種器官保存液灌洗並 低溫保存等待移植？",
        "選項": [
            "A. Saline Solution",
            "B. HTK Solution",
            "C. HAES Solution",
            "D. Ringer's Solution",
            "E. Lactate ringer's Solution"
        ],
        "答案": "B",
        "出處": "Peter J. Morris Kidney\nTransplantation-Principles and\nPractice. 2020, 8th ed, Chapter 9"
    },
    {
        "題別": "單",
        "題號": "57",
        "題目": "血型A型病人接受血型B型捐贈者的腎臟進行血型不相容腎 臟移植後，如果需要輸冷凍血漿(fresh frozen plasma)，應 該輸什麼血型的？",
        "選項": [
            "A. A型。",
            "B. O型。",
            "C. AB型。",
            "D. O型，不過冷凍血漿解凍後必須先經過放射線照射。",
            "E. 都可以，不過冷凍血漿解凍後必須先經過放射線照射。"
        ],
        "答案": "C",
        "出處": "Am J Transplant. 2016\nMar;16(3):886-96."
    },
    {
        "題別": "單",
        "題號": "58",
        "題目": "下列那一類病人不適合接受肝臟移植？",
        "選項": [
            "A. 肝衰竭合併食道靜脈曲張出血。",
            "B. 肝硬化合併反覆肝昏迷。",
            "C. 不可逆的心因性休克所導致的急性肝衰竭。",
            "D. 膽道閉鎖合併反覆膽管感染。",
            "E. Milan criteria 內肝癌病人但有五年來沒復發的乳癌。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery: The\nBiological Basis of Modern Surgical\nPractice 21st ed, 2022, Chap 26,\np614-8"
    },
    {
        "題別": "單",
        "題號": "59",
        "題目": "Ｂ型肝炎肝硬化病人接受肝移植後的長期藥物清單裏一定 比其他肝移植病人多含了以下何者？",
        "選項": [
            "A. 抗排斥藥。",
            "B. Nucleos(t)ide analogues。",
            "C. 類固醇。",
            "D. 直接抗病毒藥物（Direct-acting antiviral agent, DAA）。",
            "E. Ｂ型肝炎免疫球蛋白（hepatitis B immunoglobulin, HBIG）。"
        ],
        "答案": "B",
        "出處": "Sabiston Textbook of Surgery: The\nBiological Basis of Modern Surgical\nPractice 21st ed, 2022, Chap 26,\np614-8"
    },
    {
        "題別": "單",
        "題號": "60",
        "題目": "肝移植手術後病人追蹤有新產生的黃疸，請問下列那項檢 查不必要？",
        "選項": [
            "A. 腹部超音波。",
            "B. 核磁共振膽胰道攝影術(MRCP)。",
            "C. 尿蛋白。",
            "D. 病毒量 (如HBV, CMV, EBV)。",
            "E. 抗排斥藥濃度。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery: The\nBiological Basis of Modern Surgical\nPractice 21st ed, 2022, Chap 26,\np621-2"
    },
    {
        "題別": "單",
        "題號": "61",
        "題目": "目前臨床使用末期肝病模式指標（MELD score）來評估肝 功能喪失的嚴重程度，作為分配器官(肝臟)優先順序的依據 ，以下那一項檢驗項目不包含在MELD score的計算公式之 內？",
        "選項": [
            "A. 肌酐酸 (Creatinine)",
            "B. 白蛋白 (Albumin)",
            "C. 總膽紅素 (Bilirubin)",
            "D. 凝血酶原時間之國際標準化比值（international normalized ratio，簡稱INR）",
            "E. 血清中的鈉濃度(Serum sodium）。"
        ],
        "答案": "B",
        "出處": "行政院衛生福利部函 /發文日\n期：中華民國壹百零八年六月二\n十四日/發文字號：衛部醫字第\n1081668441A號 難度: 簡單"
    },
    {
        "題別": "單",
        "題號": "62",
        "題目": "膽道閉鎖的兒童，有以下狀況，應考慮肝臟移植，何者除 外？",
        "選項": [
            "A. 有大量腹水。",
            "B. 腹腔內有明顯的靜脈曲張。",
            "C. 有顯著的肝脾腫大。",
            "D. 接受葛西氏手術後3個月，黃疸持續上升。",
            "E. 麩丙轉胺酶（Alanine transaminase，ALT）持續高於正 常值2倍。"
        ],
        "答案": "E",
        "出處": "Jane Hartley 及 Deirdre Kelly\nPediatric Liver Transplantation, 2021\nby Elsevier, Inc. 34, 344-350 難度:\n簡單"
    },
    {
        "題別": "單",
        "題號": "63",
        "題目": "為了避免在ABO血型不符的肝臟移植後，發生超急性排斥 或抗體介導排斥反應（Antibody-mediated rejection, AMR）以下那一種做法的效果最不顯著？",
        "選項": [
            "A. 手術前7-14天給予莫須瘤( Rituximab，a monoclonal anti-CD20 antibody)。",
            "B. 手術前進行血漿分離術(Plasmapheresis)。",
            "C. 在手術前將 anti-A/B isoagglutinins 降低至 1:16 或更 低。",
            "D. 手術前給予高劑量靜脈注射免疫 球蛋白(High-dose IVIGs)。",
            "E. 手術後使用三種抗排斥藥 (Triple-drug immunosuppression: tacrolimus, mycophenolate mofetil, steroids)。"
        ],
        "答案": "D",
        "出處": "Piotr Kaliciński 及 Joanna\nPawłowska\nPediatric Liver Transplantation, 2021\nby Elsevier, Inc. 9, 70-78 難度: 中\n等"
    },
    {
        "題別": "單",
        "題號": "64",
        "題目": "有關活體捐肝肝臟移植手術，下列敘述何者正確？",
        "選項": [
            "A. 如果捐肝者正常的話，GRWR(donor graf to recipient body weight ratio) 0.8至1.0%是合適的大小。",
            "B. 如果捐肝者有脂肪肝的話，GRWR可已降到0.6%以 下。",
            "C. 活體捐肝者幾乎沒有死亡風險。",
            "D. 捐肝者如果是有脂肪肝的話，剩餘的肝臟維持20%即很 安全。",
            "E. 在台灣朋友之間可以活體捐贈肝臟做移植手術。"
        ],
        "答案": "A",
        "出處": "Sabiston Textbook of Surgery, 20\ned, 2017, Chapter 26, 614-626"
    },
    {
        "題別": "單",
        "題號": "65",
        "題目": "心臟移植病患，術後一年後死亡原因，下列何者最常見？",
        "選項": [
            "A. Acute rejection。",
            "B. Cardiac allograft vasculopathy。",
            "C. Infection。",
            "D. Malignancy。",
            "E. Primary graft failure。"
        ],
        "答案": "B",
        "出處": "Awad MA, Shah A, Griffith BP.\nCurrent status and outcomes in heart\ntransplantation: a narrative review.\nRev Cardiovasc Med. 2022 Jan\n11;23(1):11"
    },
    {
        "題別": "單",
        "題號": "66",
        "題目": "末期心臟衰竭病患，接受心臟移植評估，病人的肺血管阻 力(pulmonary vascular resistance) ，一般建議不宜超過多 少？",
        "選項": [
            "A. 1 Wood units",
            "B. 2 Wood units",
            "C. 3 Wood units",
            "D. 6 Wood units",
            "E. 9 Wood units"
        ],
        "答案": "D",
        "出處": "Cardiac Surgery, Kirklin/Barratt-\nBoyes 4th edition 2013, Part IV\nChapter 21 Page 820"
    },
    {
        "題別": "單",
        "題號": "67",
        "題目": "心臟移植病患，術後容易發生癌症，下列何者最常見？",
        "選項": [
            "A. Lung cancer。",
            "B. Colon cancer。",
            "C. Lymphoma。",
            "D. Skin cancer。",
            "E. Hepatocellular carcinoma。"
        ],
        "答案": "D",
        "出處": "Awad MA, Shah A, Griffith BP.\nCurrent status and outcomes in heart\ntransplantation: a narrative review.\nRev Cardiovasc Med. 2022 Jan\n11;23(1):11."
    },
    {
        "題別": "單",
        "題號": "68",
        "題目": "李小英是一位末期腎病病患，已常規接受血液透析治療， 她的親友有意捐贈腎臟給他，根據臺灣現行人體器官移植 條例，請問下列那一位符合捐贈資格？",
        "選項": [
            "A. 已訂婚的未婚夫，三十五歲。",
            "B. 姐夫，四十一歲(姻親)。",
            "C. 好朋友，國小同學，三十八歲(無關係) 。",
            "D. 堂哥，四十六歲(伯伯的兒子，四等血親)。",
            "E. 與前夫所生十五歲的兒子(一等血親)。"
        ],
        "答案": "D",
        "出處": "參考資料：人體器官移植條例\n(民國 104 年 7 月 1 日 修正)"
    },
    {
        "題別": "單",
        "題號": "69",
        "題目": "請問以下何者不是常用的器官保存液？",
        "選項": [
            "A. Euro-Collins solution",
            "B. Celsior solution",
            "C. Alanyl glutamine solution",
            "D. Histidine-tryptonphan-ketoglutarate (HTK) solution",
            "E. University of Wisconsin (UW) solution"
        ],
        "答案": "C",
        "出處": "Hosgood, Advances in Kidney\nPreservation Techniques and Their\nApplication in Clinical Practice,\nTransplantation, 2021"
    },
    {
        "題別": "單",
        "題號": "70",
        "題目": "關於活體腎臟移植，下列敍述何者為非？",
        "選項": [
            "A. 活體腎臟移植之器官存活率優於大愛腎臟移植。",
            "B. 活體腎臟捐贈者將來需接受透析的機率在捐贈後會增 加。",
            "C. 活體腎臟捐贈手術死亡風險約為三千分之一。",
            "D. 活體腎臟捐贈後之心血管疾病風險較相同條件之健康族 群明顯增加。",
            "E. 活體腎臟切除手術偏好左側腎臟原因為腎靜脈較長。"
        ],
        "答案": "D",
        "出處": "Lam, Long-term medical risks to the\nliving kidney donor, Nature Reviews\nNephrology, 2015"
    },
    {
        "題別": "單",
        "題號": "71",
        "題目": "以下何種原因之昏迷，仍可判定腦死？",
        "選項": [
            "A. 新陳代謝障礙期間",
            "B. 藥物中毒期間",
            "C. 缺氧",
            "D. 低體溫期間",
            "E. 原因不明"
        ],
        "答案": "C",
        "出處": "腦死判定準則。衛福部\n2012/12/17。衛署醫字第\n101026782號"
    },
    {
        "題別": "單",
        "題號": "72",
        "題目": "有關腎臟之保存，以下何者為非？",
        "選項": [
            "A. 多數活體捐腎之保存使用Lactated Ringer's Solution即 可，因為缺血時間一般很短。",
            "B. 保存時間長短可以影響腎臟的功能，如果保存時間大於 72小時，Acute Tubular Necrosis就成為使腎臟功能受損的 一大因素了。",
            "C. 保存時間長時，保存溶液的成份相對就重要了，目前 UW-1 Solution是最常用的溶液。",
            "D. 短的Cold ischemia time時需要Extracellular Solution來 保存，而Cold ischemia time長時，則需要Intracellular Solution作為保存溶液。",
            "E. 使用UW-1 Solution可以明顯改善肝臟的保存，又因為大 約80﹪的捐贈者屬於多器官捐贈，所以UW-1也成為最常用 的腎臟保存液了。"
        ],
        "答案": "A",
        "出處": "Campbell’s Urology, 12th\ned.,2020。\nAbdominal Organ Transplantation,\n1st ed., 2016, Organ Preservation\nand Perfusion, p. 21–29"
    },
    {
        "題別": "單",
        "題號": "73",
        "題目": "一名足月生6個月大之嬰兒，因重度腦部外傷住院，昏迷指 數為3，需持續依賴人工呼吸器。影像顯示不可逆腦部結構 損壞，體溫正常，藥物排除完畢。原診治醫師欲進行腦死 判定。下列關於本個案腦死判定的流程，何者敘述正確？",
        "選項": [
            "A. 若病情明確，無須觀察期即可執行第一次腦幹功能測 試。",
            "B. 兩次腦幹功能測試之間應至少間隔24小時。",
            "C. 判定應由兩位具神經外科專科資格醫師共同執行。",
            "D. 應先觀察至少72小時，並由具腦死判定資格之兒科專科 醫師參與判定。",
            "E. 若第二次測試符合無呼吸與反射消失，即可單獨簽署腦 死認定書。"
        ],
        "答案": "B",
        "出處": "腦死判定準則。衛福部\n2012/12/17。衛署醫字第\n101026779號"
    },
    {
        "題別": "單",
        "題號": "74",
        "題目": "一位血型 A 型的病人接受來自血型 B 型捐贈者的腎臟移植 手術（ABO 不相容腎臟移植）後，術中因失血需要輸注濃 縮紅血球（PRBC）。此時應輸注那一血型的 PRBC 最為 安全？",
        "選項": [
            "A. A 型",
            "B. B 型",
            "C. AB 型",
            "D. O 型",
            "E. 只要經照射處理，任一血型皆可輸注。"
        ],
        "答案": "A",
        "出處": "Thomas E. Starzl Transplantation\nTextbook, 2nd ed., 2018 Chapter\n17 ABO-Incompatible\nTransplantation p. 311"
    },
    {
        "題別": "單",
        "題號": "75",
        "題目": "下列那一項不是美國醫療保險與醫療補助服務中心（ CMS）所列舉的小腸移植建議適應症？",
        "選項": [
            "A. 因長期接受靜脈營養導致的肝硬化與門脈高壓。",
            "B. 中央靜脈導管感染每年超過兩次，需住院治療。",
            "C. 中樞靜脈導管相關真菌血症曾發生一次。",
            "D. 因家庭拒絕照護，病人不願接受長期居家靜脈營養。",
            "E. 小腸切除後殘餘腸長 60 公分，但病人可維持口服進食 與營養。"
        ],
        "答案": "E",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "76",
        "題目": "關於與長期全靜脈營養（TPN）相關之腸道衰竭相關肝病 （IFALD）的敘述，下列何者錯誤？",
        "選項": [
            "A. IFALD 可在使用 TPN 超過兩週後發生，其生化特徵包 括共軛型膽紅素大於 2 mg/dL。",
            "B. IFALD 是小腸衰竭病人接受小腸移植的常見指標之一。",
            "C. IFALD 在兒童中發生率高，與使用 TPN 超過 3 個月的 時間密切相關。",
            "D. 成人居家 TPN 病人罹患 IFALD 的風險約為 15–40%， 遠低於兒童。",
            "E. 若共軛型膽紅素上升，但肝功能其餘指數正常，則不需 考慮移植。"
        ],
        "答案": "E",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "77",
        "題目": "關於小腸移植與其他器官（如肝臟或腎臟）移植病人評估 流程的比較，下列哪一項較常為小腸移植候選人所特有， 並非所有器官移植前常規評估項目？",
        "選項": [
            "A. 人類白血球抗原（HLA）分型與抗體檢查。",
            "B. 腹部與骨盆腔電腦斷層掃描。",
            "C. 胃排空與腸道動力檢查（motility testing）。",
            "D. 心臟超音波檢查與肺功能評估。",
            "E. 貧血、凝血與肝功能常規抽血檢查。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "78",
        "題目": "關於屍體捐贈者作為小腸移植供體的選擇標準，下列那一 項敘述錯誤？",
        "選項": [
            "A. 小腸移植接受者常因多次腹部手術導致腹腔容積減少， 故選擇體重比受者小 50–75% 的供體有助於減少腹壓相關 併發症。",
            "B. 小腸移植物對冷缺血特別敏感，因此建議冷缺血時間應 控制在 6–8 小時以內。",
            "C. 若捐贈者有曾接受過重大腹部手術的病史，仍可考慮使 用其小腸供體，只要血型與大小匹配。",
            "D. 捐贈者的 CMV 與 EBV 血清檢測是必要的，因為病毒傳 播可能導致移植後嚴重併發症。",
            "E. 最佳的小腸供體應為血流穩定、需最少升壓劑支持，且 地理上鄰近受贈者中心。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "79",
        "題目": "關於小腸移植手術，下列何者敘述正確？",
        "選項": [
            "A. 小腸移植供體理想體重為受贈者的1.5至2倍，以確保足 夠腸長。",
            "B. 小腸對冷缺血時間容忍度高，可容許超過12小時的保存 時間。",
            "C. 腸道移植供體需另行摘取頸動脈或髂動脈作為血管重建 用。",
            "D. 移植時不需行迴腸造口，可直接與受者乙狀結腸吻合。",
            "E. 腸移植術後通常不需持續觀察吻合口，可憑血清標記物 追蹤排斥情形。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "80",
        "題目": "關於小腸移植的移植類型（types of intestinal transplantation），以下敘述何者正確？",
        "選項": [
            "A. 單獨小腸移植（Isolated intestine transplant）無法用於 肝功能正常的病人。",
            "B. 修改型多臟器移植（Modified multivisceral transplant） 通常包含肝臟。",
            "C. 多臟器移植（Multivisceral transplant）至少包含胃、小 腸與肝臟。",
            "D. 肝-小腸聯合移植（Liver–intestine transplant）常用於因 靜脈營養導致肝衰竭者。",
            "E. Cluster移植指的是僅移植胃與小腸，供血來自多條動脈 分支。"
        ],
        "答案": "D",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "81",
        "題目": "關於小腸移植後免疫抑制策略的敘述，下列何者為非？",
        "選項": [
            "A. 小腸移植常採用抗胸腺球蛋白（antithymocyte globulin）或 monoclonal antibody 作為誘導性免疫抑制。",
            "B. 維持性免疫抑制常以 Tacrolimus 為基礎，有時會合併使 用 Mycophenolate mofetil 或 Sirolimus。",
            "C. 腸道移植接受者常需較強的免疫抑制，可能與腸黏膜相 關淋巴組織及菌群相關。",
            "D. 若出現 Tacrolimus 引起的腎毒性，可考慮使用 Belatacept 作為替代。",
            "E. 為避免潛在副作用，目前多數中心已完全不再使用類固 醇作為免疫抑制藥物之一。"
        ],
        "答案": "E",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "82",
        "題目": "關於小腸移植急性細胞性排斥（Acute Cellular Rejection） 的病理學特徵與診斷方式，下列敘述何者正確？",
        "選項": [
            "A. 小腸移植排斥的診斷主要依靠血中 citrulline 或 stool calprotectin 的變化。",
            "B. 嚴重排斥時，組織學上仍可觀察到完整的腸絨毛與腺體 結構。",
            "C. 中度排斥會出現明顯的絨毛扁平化及固有層(lamina propria) 的高度發炎反應。",
            "D. 由於腸道位置深且無法內視鏡觀察，活檢並非診斷排斥 的方式。",
            "E. 輕度排斥主要由腸道平滑肌層發炎細胞浸潤所構成。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "83",
        "題目": "一位 7歲男童，因先天性腸閉鎖合併短腸症接受單純小腸移 植，目前術後第6個月。最近出現持續低燒、倦怠、體重減 輕、頸部淋巴結腫大。實驗室發現 EBV DNA 明顯上升， 移植腸道未見明顯排斥跡象。以下何者最可能的診斷？",
        "選項": [
            "A. 急性排斥反應（Acute cellular rejection）",
            "B. 巨細胞病毒腸炎（CMV enteritis）",
            "C. 免疫抑制劑相關毒性腸炎（Immunosuppressive-related enteritis）",
            "D. 移植物相關淋巴增生疾病（Posttransplant lymphoproliferative disorder, PTLD）",
            "E. 腸道吻合處瘻管感染（Anastomotic fistula infection）"
        ],
        "答案": "D",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "84",
        "題目": "下列關於小腸移植後CMV（巨細胞病毒）感染的敘述，何 者正確？",
        "選項": [
            "(A). CMV感染發生率低於10%，不建議常規監測。",
            "(B). CMV感染多發生於接受CMV陰性捐贈者的受贈者。",
            "(C). CMV IVIG主要用於無症狀感染者的預防性使用。",
            "(D). CMV感染可能表現為腹瀉、腹痛，需與排斥鑑別。",
            "(E). CMV感染時應立即停用所有免疫抑制劑。"
        ],
        "答案": "D",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65"
    },
    {
        "題別": "單",
        "題號": "85",
        "題目": "關於小腸移植後急性排斥的監測與診斷，下列敘述何者正 確？",
        "選項": [
            "A. 血清calprotectin是目前廣泛使用的腸道排斥生化指標。",
            "B. 小腸移植後排斥常有典型症狀，便於早期辨識。",
            "C. Donor-specific antibodies (DSAs) 在移植後無需定期監 測。",
            "D. 小腸移植後可透過造口進行活體病理切片監測。",
            "E. 組織學上，輕度急性排斥會有嚴重黏膜潰瘍及絨毛破 壞。"
        ],
        "答案": "D",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "86",
        "題目": "有關人類白血球抗原（HLA）在器官移植中的角色，下列 何者正確？",
        "選項": [
            "A. 混合淋巴球反應（MLR）能快速精確辨識雙方所有HLA 基因型差異。",
            "B. 與傳統細胞學方法相比，現代分子技術無法進行Class II 位點的高解析度定序。",
            "C. 零抗原不匹配（Zero-antigen mismatch）通常指A、",
            "B、DR六個位點的完全配對。",
            "D. HLA-C、DP、DQ從未被納入器官分配的考量，且無需 報告其基因型。",
            "E. 類型一（Class I）HLA typing目前以分子生物技術為主 流，血清學方法已完全淘汰。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "87",
        "題目": "在進行器官移植前的交叉配對與供體特異性抗體（DSA, donor specific antibody）評估，下列敘述何者正確？",
        "選項": [
            "A. 傳統補體依賴性淋巴毒性試驗（complement- dependent cytotoxicity crossmatch）無法檢測 IgG 類抗 體。",
            "B. 陽性交叉配對通常表示移植風險高，建議照常移植並加 強免疫抑制。",
            "C. Luminex 分析法可檢測接受者血清中對特定 HLA 抗原 的抗體。",
            "D. DSA 僅在急性細胞性排斥時才會出現，與慢性排斥無 關。",
            "E. 所有移植中心皆採固定的 DSA 監測頻率與治療指引。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 28, 644-65, 2021"
    },
    {
        "題別": "單",
        "題號": "88",
        "題目": "關於3D列印（3D printing）與3D生物列印（3D bioprinting）在醫學領域的應用，下列敘述何者正確？",
        "選項": [
            "A. 目前3D列印在醫學的應用佔整體產業比重已超過50%， 並廣泛取代器官移植。",
            "B. 3D生物列印僅限於堅硬組織（如骨頭）建構，無法應用 於皮膚或神經等軟組織。",
            "C. 利用病人特有的解剖數據製作的3D模型，可協助外科醫 師進行術前模擬與手術演練。",
            "D. 已有多項3D列印器官通過臨床試驗並納入常規移植療 程。",
            "E. 3D生物列印應用僅限於藥物開發，尚無醫學臨床用途。"
        ],
        "答案": "C",
        "出處": "Sabiston Textbook of Surgery,\nChapter 15, 349-361.e1, 2021"
    },
    {
        "題別": "單",
        "題號": "89",
        "題目": "高齡肝臟移植者的免疫與併發症風險，關於65歲以上患者 接受肝臟移植的敘述，下列何者正確？",
        "選項": [
            "A. 年長患者接受肝移植後的排斥率高，需加強免疫抑制治 療。",
            "B. 年長患者住院中若表現健康（如住家中而非機構），其 年齡對預後影響不大。",
            "C. 肝移植後的感染與惡性腫瘤風險在年長者中較低。",
            "D. 年長肝臟受贈者應一律採用年輕供體肝臟以提升成功 率。",
            "E. 高齡患者不適合進行肝臟移植，建議保守治療為主。"
        ],
        "答案": "B",
        "出處": "Sabiston Textbook of Surgery,\nChapter 13, 284-314, 2021"
    },
    {
        "題別": "單",
        "題號": "90",
        "題目": "關於移植術前及術後之donor-specific antibody (DSA) 評估 與其臨床意義，下列敘述何者正確？",
        "選項": [
            "A. 術前存在DSA者如CDC crossmatch陰性，可視為低風險 ，無需額外處置。",
            "B. 術後產生de novo DSA者與慢性排斥無顯著相關，因此 臨床上可不需常規監測。",
            "C. DSA常透過flow cytometry crossmatch檢出，臨床上最 具特異性的是IgM類抗體。",
            "D. 高強度DSA與移植後兩年內的移植物功能喪失顯著相關 ，應納入術後定期監測項目。",
            "E. 若DSA存在但患者無明顯臨床症狀與生化異常，則無需 進行移植病理切片或進一步處置。"
        ],
        "答案": "D",
        "出處": "Cellular and Molecular Immunology.\n9th ed. Philadelphia: Elsevier; 2018."
    }
]